FDG-PET/CT identified distant metastases and synchronous cancer in squamous cell carcinoma of the head and neck: the impact of smoking and P16-s.
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
02
03
2021
accepted:
17
05
2021
pubmed:
3
6
2021
medline:
11
1
2022
entrez:
2
6
2021
Statut:
ppublish
Résumé
Whole-body FDG-PET-CT is widely used at diagnosis of squamous cell carcinoma of the head and neck (SCCHN) but may identify suspicious lesions outside the neck that require investigation. This study evaluated the impact of smoking and P16-status on the incidence of malignant disease outside the head and neck region in newly diagnosed patients with SCCHN. All PET-positive foci outside the head-neck area were registered in 1069 patients planned for postoperative or curative intent radiotherapy with whole-body FDG-PET/CT from 2006 to 2012. All patient files were retrospectively investigated and clinical parameters, tobacco use, HPV (P16)-status and subsequent malignant disease registered. Malignancy outside the neck was diagnosed in 9% of smokers, 2% of never-smokers, and 5% of patients with P16-positive oropharyngeal squamous cell carcinoma (OPSCC). Clinically suspicious PET-positive foci outside the head-neck were malignant in 55% of smokers, 34% of never-smokers, and in 38% of P16-pos OPSCC. All but two patients with cancer occurring outside the head and neck region were smokers. Malignancy outside the neck at diagnosis was more frequent in smokers compared to non-smokers or P16-pos OPSCC. A high proportion of clinically suspicious PET-positive foci were non-malignant.
Identifiants
pubmed: 34075488
doi: 10.1007/s00405-021-06890-7
pii: 10.1007/s00405-021-06890-7
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-526Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Manca G, Vanzi E, Rubello D et al (2016) (18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications. Eur J Nucl Med Mol Imaging 43(7):1360–1375. https://doi.org/10.1007/s00259-015-3294-0
doi: 10.1007/s00259-015-3294-0
pubmed: 26780912
pmcid: 26780912
Rohde M, Nielsen AL, Johansen J et al (2017) Head-to-Head comparison of chest X-Ray/head and neck MRI, chest CT/head and neck MRI, and (18)F-FDG PET/CT for detection of distant metastases and synchronous cancer in oral, pharyngeal, and laryngeal cancer. J Nucl Med 58(12):1919–1924. https://doi.org/10.2967/jnumed.117.189704
doi: 10.2967/jnumed.117.189704
pubmed: 28572489
pmcid: 28572489
Kim Y, Roh JL, Kim JS et al (2019) Chest radiography or chest CT plus head and neck CT versus (18)F-FDG PET/CT for detection of distant metastasis and synchronous cancer in patients with head and neck cancer. Oral Oncol 88:109–114. https://doi.org/10.1016/j.oraloncology.2018.11.026
doi: 10.1016/j.oraloncology.2018.11.026
pubmed: 30616780
pmcid: 30616780
Pedraza S, Ruiz-Alonso A, Hernandez-Martinez AC, Cabello E, Lora D, Perez-Regadera JF (2019) (18)F-FDG PET/CT in staging and delineation of radiotherapy volume for head and neck cancer. Rev Esp Med Nucl Imagen Mol 38(3):154–159. https://doi.org/10.1016/j.remn.2018.08.002
doi: 10.1016/j.remn.2018.08.002
pubmed: 30655026
pmcid: 30655026
Carlander AF, Gronhoj Larsen C, Jensen DH et al (2017) Continuing rise in oropharyngeal cancer in a high HPV prevalence area: a Danish population-based study from 2011 to 2014. Eur J Cancer 70:75–82. https://doi.org/10.1016/j.ejca.2016.10.015
doi: 10.1016/j.ejca.2016.10.015
pubmed: 27888679
pmcid: 27888679
Stokkel MP, Moons KG, ten Broek FW, van Rijk PP, Hordijk GJ (1999) 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 86(11):2370–2377
doi: 10.1002/(SICI)1097-0142(19991201)86:11<2370::AID-CNCR27>3.0.CO;2-B
Yankevich U, Hughes MA, Rath TJ et al (2017) PET/CT for Head and Neck squamous cell carcinoma: should we routinely include the head and abdomen? AJR Am J Roentgenol 208(4):844–848. https://doi.org/10.2214/ajr.16.16320
doi: 10.2214/ajr.16.16320
pubmed: 28177644
pmcid: 28177644
Haerle SK, Schmid DT, Ahmad N, Hany TF, Stoeckli SJ (2011) The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol 47(7):653–659. https://doi.org/10.1016/j.oraloncology.2011.05.011
doi: 10.1016/j.oraloncology.2011.05.011
pubmed: 21658990
pmcid: 21658990
Ng SH, Chan SC, Liao CT et al (2008) Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology 50(11):969–979. https://doi.org/10.1007/s00234-008-0426-2
doi: 10.1007/s00234-008-0426-2
pubmed: 18600319
pmcid: 18600319
Kaida H, Ishibashi M, Kurata S et al (2009) The utility of FDG-PET for detecting multiple primary cancers in hypopharyngeal cancer patients. Nuklearmedizin 48(5):179–184. https://doi.org/10.3413/nukmed-0228
doi: 10.3413/nukmed-0228
pubmed: 19639163
pmcid: 19639163
Beatty JS, Williams HT, Aldridge BA et al (2009) Incidental PET/CT findings in the cancer patient: how should they be managed? Surgery 146(2):274–281. https://doi.org/10.1016/j.surg.2009.04.024
doi: 10.1016/j.surg.2009.04.024
pubmed: 19628085
pmcid: 19628085
Strobel K, Haerle SK, Stoeckli SJ et al (2009) Head and neck squamous cell carcinoma (HNSCC)–detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 36(6):919–927. https://doi.org/10.1007/s00259-009-1064-6
doi: 10.1007/s00259-009-1064-6
pubmed: 19205699
pmcid: 19205699
Sharp L, McDevitt J, Carsin A-E, Brown C, Comber H (2014) Smoking at diagnosis is an independent prognostic factor for cancer-specific survival in head and neck cancer: findings from a large, population-based study. Cancer Epidemiol Biomark Prev 23(11):2579–2590. https://doi.org/10.1158/1055-9965.EPI-14-0311
doi: 10.1158/1055-9965.EPI-14-0311
Ng SP, Pollard C 3rd, Kamal M et al (2019) Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol 3:22. https://doi.org/10.1038/s41698-019-0097-y
doi: 10.1038/s41698-019-0097-y
pubmed: 31583278
pmcid: 31583278
Veit-Haibach P, Luczak C, Wanke I et al (2007) TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging 34(12):1953–1962. https://doi.org/10.1007/s00259-007-0564-5
doi: 10.1007/s00259-007-0564-5
pubmed: 17717661
pmcid: 17717661
Zimmer LA, Branstetter BF, Nayak JV, Johnson JT (2005) Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 115(11):2029–2034. https://doi.org/10.1097/01.mlg.0000181495.94611.a6
doi: 10.1097/01.mlg.0000181495.94611.a6
pubmed: 16319618
pmcid: 16319618
Xu GZ, Guan DJ, He ZY (2011) (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis Oral Oncol 47(7):560–565. https://doi.org/10.1016/j.oraloncology.2011.04.021
doi: 10.1016/j.oraloncology.2011.04.021
pubmed: 21621450
pmcid: 21621450
Kim SY, Roh JL, Yeo NK et al (2007) Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 18(10):1698–1703. https://doi.org/10.1093/annonc/mdm270
doi: 10.1093/annonc/mdm270
pubmed: 17716985
pmcid: 17716985